Approval12 Jul 2021 07:15
Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicine company - Enters service agreement with Aptuit SRL, a subsidiary of drug discovery and development company Evotec SE. "This agreement will use Evotec's technology platform to expedite the development of OCTP's lead compound, OCT461201, a selective cannabinoid receptor type 2 agonist, towards Phase 1 clinical trials. This Phase 1 clinical trial will be aimed at demonstrating the safety and tolerabililty of the drug product," company
Will buy if it drop below 3p as I believe will drop further . The future looks good long term for this company but uncertainty with approval and legalising in the UK. eventually though science will prevail over legislation.